Related Experiment Video
Updated: May 26, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Synthesis of entecavir and its novel class of analogs
Ravindra K Rawal1, Uma Sharan Singh, Srinivas Gadthula
1The University of Georgia College of Pharmacy, Athens, Georgia, USA.
Abstract:
Due to the slow kinetics of viral clearance and the spontaneous genetic variability of hepatitis B virus (HBV), antiviral therapy of chronic hepatitis B remains a clinical challenge. Entecavir (S.10; a 2'-deoxy carbocyclic guanosine analog with an exo-cyclic double bond on the 5'-position; Fig. 14.7.1) has been approved in the U.S. for the therapy of chronic hepatitis B. Entecavir is synthesized from D-ribose via a key allylic alcohol (S.3) intermediate. This intermediate is also utilized to synthesize entecavir-modified carbocyclic nucleosides S.13, S.15, S.19, and S.22.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Subviral Agents
Inhibitors of Bacterial DNA Synthesis
Retroviruses
Retrovirus Life Cycles
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...

